| Literature DB >> 24619691 |
Hidekazu Shirota1, Dennis M Klinman.
Abstract
The primary goal of cancer vaccines is to elicit tumor-specific cytotoxic T lymphocytes (CTL) capable of eradicating established tumors and preventing/eradicating their metastatic spread. CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Thus, CpG ODN are effective vaccine adjuvants. The adjuvant activity of CpG ODN is improved by maintaining them in close physical and temporal proximity to the co-administered vaccine antigen. This work describes a method of chemically conjugating CpG ODN to antigens and/or cancer cells that improve the resulting CTL response.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24619691 PMCID： PMC6457254 DOI： 10.1007/978-1-4939-0345-0_27
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745